Jung Won Shin
Jung Won focuses on coverage of all aspects of news in the Korean pharma and biotech industry as well as for regulatory matters. She covers major pharma and biotech conferences in Korea as well as interviewing key opinion leaders. She also handles a regular Korean language podcast on Scrip/Pink Sheet stories. She has worked previously for Dow Jones Newswires, covering various industry sectors and the economy.
Latest From Jung Won Shin
Amid a generally harsh environment, venture capital investors in South Korea appeared to take a more selective approach in 2022, with more established and financially stable domestic bioventures the biggest beneficiaries.
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.
As the global biopharma industry attempts to understand the implications of the US Inflation Reduction Act, South Korea's biopharma industry is pressing its government to come up with "bold and rapid" additional measures to reduce the possible negative impact of the legislation and other US policies with international implications, and to support the sector amid generally rising global competition.
Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.
Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.